Will Furosemide (Lasix) interfere with the action of Fluconazole (Diflucan)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Furosemide (Lasix) and Fluconazole (Diflucan) Drug Interaction

Furosemide (Lasix) does not significantly interfere with the therapeutic action of fluconazole (Diflucan), but their concurrent use requires monitoring due to potential additive nephrotoxicity. While these medications don't directly reduce each other's efficacy, their combined use warrants attention to potential adverse effects.

Mechanism of Interaction

Fluconazole is an azole antifungal that works by inhibiting the cytochrome P450 enzyme system, particularly CYP3A4 and CYP2C9 enzymes 1. This inhibition can affect the metabolism of many medications, but furosemide is not primarily metabolized through these pathways.

The main concern with concurrent use is not reduced efficacy but rather:

  1. Potential for additive nephrotoxicity
  2. Electrolyte disturbances
  3. Increased risk of QTc prolongation

Clinical Significance and Monitoring

When using these medications together:

  • Monitor renal function: Both medications can affect kidney function, with furosemide potentially causing dehydration and pre-renal azotemia, while fluconazole may have direct nephrotoxic effects 2, 3.

  • Check electrolytes: Furosemide causes potassium, sodium, and magnesium wasting, which could exacerbate any electrolyte imbalances during antifungal therapy 4.

  • Watch for QTc prolongation: Fluconazole can cause QTc prolongation, and electrolyte abnormalities from furosemide (especially hypokalemia) may increase this risk 1.

Special Populations

Patients with Renal Impairment

Patients with existing renal impairment require extra caution as both medications can affect kidney function. The 2024 guidelines recommend careful dose adjustment of furosemide in patients with renal insufficiency 4.

Patients on Multiple Medications

The risk of adverse reactions increases in patients receiving multiple medications 5. A retrospective study found that while potential drug-drug interactions with azoles were common (70.3% of admissions), clinically significant adverse events were relatively rare 6.

Recommendations for Clinical Practice

  1. Baseline assessment: Obtain baseline renal function and electrolytes before initiating combination therapy.

  2. Regular monitoring: Monitor renal function and electrolytes, particularly potassium, during concurrent therapy.

  3. Dose adjustments: Consider lower initial doses of furosemide in patients receiving fluconazole, especially in those with pre-existing renal impairment.

  4. Hydration status: Maintain adequate hydration to reduce the risk of nephrotoxicity.

  5. Alternative diuretics: In high-risk patients, consider alternative diuretics if appropriate for the clinical situation.

Conclusion

While furosemide does not directly interfere with the antifungal action of fluconazole, their concurrent use requires monitoring for potential additive nephrotoxicity and electrolyte disturbances. The combination can be used safely with appropriate monitoring and dose adjustments when clinically indicated.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Drug-drug interactions with systemic antifungals in clinical practice.

Pharmacoepidemiology and drug safety, 2007

Research

The potential risk factors of nephrotoxicity during vancomycin therapy in Chinese adult patients.

European journal of hospital pharmacy : science and practice, 2021

Guideline

Renal Impairment and Furosemide Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Drug interactions with itraconazole, fluconazole, and terbinafine and their management.

Journal of the American Academy of Dermatology, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.